Torrent Pharmaceuticals

Torrent Pharmaceuticals on Tuesday reported a 3.3 per cent increase in consolidated net profit at Rs 566 crore in the first quarter ended June 30, 2026. The company had posted a consolidated net profit of Rs 548 crore in the corresponding quarter last fiscal, Torrent Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations in the first quarter stood at Rs 4,921 crore as against Rs 3,178 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 4,155 crore as compared to Rs 2,403 crore in the same quarter a year ago, the company said. India revenues were at Rs 2,157 crore in the first quarter, up 19 per cent from the year-ago period, and US revenues were also at Rs 418 crore, up 36 per cent, it added. Brazil revenues stood at Rs 277 crore, up 27 per cent, and the same for Germany was at Rs 318 crore, up 3 per cent year-on-year, the company said.

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

The stock delivered higher returns than the benchmark Nifty Pharma over the past year

At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Om Mehra, tech analyst at SAMCO Securities highlights that Torrent Pharmaceuticals after a recent consolidation phase, has witnessed a strong breakout above ₹4,200 levels.

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Torrent Pharmaceuticals said the tenure of the instruments, along with the date of allotment and final maturity, will be determined at the time of issuance of NCDs

Most open offers are for a minimum of an additional stake of 26 per cent and allow public shareholders an exit after the acquisition

Torrent Pharmaceuticals Ltd on Friday said the central GST authority has imposed a penalty of over Rs 41 crore on the company for alleged erroneous refund on export of goods. The Joint Commissioner, Common Adjudicating Authority, Central GST, Ahmedabad South Commissionerate passed an order imposing a penalty of Rs 41,33,84,165, Torrent Pharmaceuticals Ltd said in a regulatory filing. The order dated November 26, 2025 alleges erroneous refund by department on export of goods, it added. The company further said based on its assessment, an appeal will be filed and is hopeful of favourable outcome and does not reasonably expect the order to have any material financial impact on it.

Torrent Pharma market capitalisation stood at ₹1.28 trillion on Monday, while that of Cipla at ₹1.22 trillion, shows BSE.

In the past one month, Torrent Pharmaceuticals has outperformed the market by surging 12%, as compared to 1.4% decline in the BSE Sensex and 4% rise in the BSE Healthcare index.

Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & ...

Torrent is acquiring a 46.39 per cent stake in JB Chemicals from KKR & Co. for about ₹11,917 crore, and an additional 2.8 per cent stake from employees for roughly ₹719 crore, both at ₹1,600 per share

Stocks to Watch Today, Monday, June 30, 2025: ITD Cementation, Asian Paints, BHEL, RVNL, Titagarh Rail System, NTPC, TVS Holdings, and Waaree Energies are some of the top stocks to watch today

Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore.

Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

The revenue grew by 3 per cent Y-o-Y to Rs 2,809 crore as markets like Brazil and the US experienced decline

The Indian pharmaceutical industry is aiming to more than double its size to USD 120-130 billion by 2030 as it looks to ride on the back of innovation to become the healthcare custodian of the world, Indian Pharmaceutical Alliance (IPA) president and Torrent Group chairman Samir Mehta said. In the last 25 years, the Indian pharma industry has grown nearly 20 times - a market size of USD 58 billion from USD 3 billion in 1999-2000, contributing equally to domestic sales and exports today. The sector is among the top five contributors to India's trade surplus, which has grown to USD 19.5 billion from merely USD 1 billion in 1999-2000. "The journey of Indian pharma is a testament to how key policy reforms coupled with entrepreneurial spirit have nurtured the sector's growth," Mehta wrote in an article on the occasion of IPA completing 25 years. "The Indian pharmaceutical sector stands at a critical juncture as India heads toward 2047. From job creation to global trade and innovation to .